In August 2022, I was diagnosed with stage 3b chronic kidney disease (CKD), indicating moderate to severe kidney function impairment. I had anticipated this diagnosis for years prior to my bilateral lung transplant in July 2021. After being diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I…
Phase 3 trials of Haduvio for chronic cough in IPF expected this year
Following the lifting of a regulatory hold late last year, a U.S. clinical trial testing LTI-03, an inhaled therapy for people with idiopathic pulmonary fibrosis (IPF), is now fully underway. Treatment developer Rein Therapeutics announced that dosing has started in the Phase 2 clinical trial, which aims to assess the…
The alarm goes off at 4:30 a.m. It is not a welcome awakening, but a stark reminder of the day ahead. The purpose of the alarm isn’t to ensure that my wife, Susan, and I are up to catch a flight that will whisk us away on vacation. It is…
Before my husband, Donnie, was diagnosed with pulmonary fibrosis (PF) in 2022, I hadn’t thought much about the importance of keeping good medical records in the event of an emergency. We were both generally healthy and didn’t take many (if any) daily prescriptions. Today, that looks much different, and…
Regulatory authorities in both the U.S. and the European Union have granted orphan drug status to deupirfenidone (LYT-100), an oral therapy Puretech Health is developing to treat idiopathic pulmonary fibrosis (IPF). This designation aims to provide extra economic incentives to companies that invest in developing medications for rare…
What do blue lobsters, green eyes, and idiopathic pulmonary fibrosis (IPF) have in common? At first glance, they may seem unrelated, but each represents something rare and extraordinary. Imagine a game board with the overarching theme of rarity, featuring categories such as unusual sea creatures, unique physical traits, and…
Mutations in the ACVRL1 gene may play a role in the development of idiopathic pulmonary fibrosis (IPF), and targeting the gene — until now, little noted, according to researchers — could potentially lead to new treatments for the respiratory disease, a study suggests. Additionally, according to the scientists, the study…
What do we want? A therapy and a cure! When do we want it? Now! Call-and-response is a tactic often used in protests. Raising many voices together to deliver the same message is a powerful force. Together as a community, we can deliver that message. The Pulmonary Fibrosis Foundation‘s (PFF)…
Treatment with Esbriet (pirfenidone) reduces the risk of irregular heartbeat by nearly 90% in adults with idiopathic pulmonary fibrosis (IPF), according to a new study. Use of the approved IPF drug also eased the worsening of atrial arrhythmias — irregular heartbeats originating in the upper chambers of the heart —…
